scholarly journals Experiencing Eight Psychotherapy Approaches Devoted to Eating Disorders in a Single Day Workshop Increases Insight and Motivation to Engage in Care

2021 ◽  
Author(s):  
Elisabetta Scanferla ◽  
Bernard Pachoud ◽  
Philip Gorwood
Keyword(s):  
Eating Disorders ◽  
Newly Diagnosed ◽  
Motivation To Change ◽  
Long Term Outcomes ◽  
Commitment To Change ◽  
Outcomes Evaluation ◽  
Number Of Patients ◽  
Almost All ◽  
Action Stage

Abstract PurposeFor patients with eating disorders (EDs), early engagement in care is usually considered as a positive prognostic factor. The aim of the present study is to investigate how a single-day intervention devoted to an early experiential exposure to a variety of psychotherapy approaches, supports transition to specialised care and commitment to change in patients with EDs.MethodsOne hundred and sixty-nine outpatients newly diagnosed with an ED took part in a single-day workshop for groups of up to 10 patients, where they discovered and experienced eight psychotherapeutic approaches. Motivation to change care, and level of insight were assessed at baseline and 10 days after the intervention.ResultsMotivation and commitment to take active steps toward change (expressed by the “Committed Action” composite score) significantly improved after intervention (p<0.001), and a significant number of patients specifically moved from “contemplation” to “action” stage (p<0.001). The improvement of motivation to change is significantly associated to an increase of insight capacity (p<0.001), and this for almost all dimensions.ConclusionA single-day session devoted to experiencing a range of group psychotherapies increased patients’ insight and motivation to actively engage in care. Further studies including different factors and long-term outcomes evaluation may be necessary to better establish which aspects are specifically involved in patients' increased motivation for care and confirm potential longer-term benefits of this intervention.Level of evidenceLevel V: Opinions of respected authorities, based on descriptive studies, narrative reviews, clinical experience, or reports of expert committees.

Change processes related to long-term outcomes in eating disorders with childhood trauma: An explorative qualitative study.

2020 ◽  
Vol 67 (1) ◽  
pp. 51-65
Author(s):  
Malin E. Olofsson ◽  
Hanne W. Oddli ◽  
Asle Hoffart ◽  
Hanna P. Eielsen ◽  
KariAnne R. Vrabel
Keyword(s):  
Eating Disorders ◽  
Qualitative Study ◽  
Childhood Trauma ◽  
Change Processes ◽  
Long Term Outcomes

scholarly journals Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Leukemia ◽  
2021 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Timothy P. Hughes ◽  
Richard A. Larson ◽  
Dong-Wook Kim ◽  
Surapol Issaragrisil ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Survival Rates ◽  
Chronic Phase ◽  
Individual Treatment ◽  
Molecular Response ◽  
Newly Diagnosed ◽  
Long Term Outcomes ◽  
Treatment Free Remission

AbstractIn the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for treatment-free remission (TFR). Cumulative 10-year rates of MMR and MR4.5 were higher with nilotinib (300 mg twice daily [BID], 77.7% and 61.0%, respectively; 400 mg BID, 79.7% and 61.2%, respectively) than with imatinib (400 mg once daily [QD], 62.5% and 39.2%, respectively). Cumulative rates of TFR eligibility at 10 years were higher with nilotinib (300 mg BID, 48.6%; 400 mg BID, 47.3%) vs imatinib (29.7%). Estimated 10-year overall survival rates in nilotinib and imatinib arms were 87.6%, 90.3%, and 88.3%, respectively. Overall frequency of adverse events was similar with nilotinib and imatinib. By 10 years, higher cumulative rates of cardiovascular events were reported with nilotinib (300 mg BID, 16.5%; 400 mg BID, 23.5%) vs imatinib (3.6%), including in Framingham low-risk patients. Overall efficacy and safety results support the use of nilotinib 300 mg BID as frontline therapy for optimal long-term outcomes, especially in patients aiming for TFR. The benefit-risk profile in context of individual treatment goals should be carefully assessed.

scholarly journals Prognostic analysis for short - and long-term outcomes of newly diagnosed epilepsy

Seizure ◽  
2017 ◽  
Vol 47 ◽  
pp. 92-98 ◽  
Author(s):  
Yong-li Jiang ◽  
Fang Yuan ◽  
Fang Yang ◽  
Xiao-long Sun ◽  
Xi-ai Yang ◽  
...  
Keyword(s):  
Newly Diagnosed ◽  
Long Term Outcomes ◽  
Prognostic Analysis ◽  
Short And Long Term

scholarly journals Investigational Immunotherapeutics for B-Cell Malignancies

2010 ◽  
Vol 28 (5) ◽  
pp. 884-892 ◽  
Author(s):  
Alfonso Quintás-Cardama ◽  
William Wierda ◽  
Susan O'Brien
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Acquired Resistance ◽  
Long Term Outcomes ◽  
Clinical Value ◽  
B Cell Malignancies ◽  
Therapeutic Algorithms ◽  
Number Of Patients

The use of rituximab-based chemoimmunotherapy regimens has remarkably improved the response rates, long-term outcomes, and quality of life of patients with B-cell malignancies. However, a substantial number of patients exhibit either primary or acquired resistance to rituximab, which suggests that novel immunotherapeutics with distinct mechanisms of action are necessary. A series of monoclonal antibodies with specificity against different surface antigens expressed on malignant B cells (eg, CD22, CD23, CD40, CD70) and novel immunotherapeutics (eg, bispecific monoclonal antibodies, small-modular immunopharmaceuticals, T-cell engagers) are currently in clinical or final preclinical stages of development. Although these agents offer reason for optimism, considerable challenges lie ahead in establishing their real clinical value, as well as in integrating them into current therapeutic algorithms for patients with B-cell malignancies. This review describes some of the most promising investigational immunotherapeutics for the treatment of B-cell malignancies.

scholarly journals Perfectionism in eating disorders: Are long-term outcomes influenced by extent and changeability in initial perfectionism?

2018 ◽  
Vol 4 (1) ◽  
pp. 1-14 ◽  
Author(s):  
Suzanne Petersson ◽  
Lars Brudin ◽  
David Clinton ◽  
Kent-Inge Perseius ◽  
Claes Norring
Keyword(s):  
Eating Disorders ◽  
Long Term Outcomes

Psychotherapy in Eating Disorders

1977 ◽  
Vol 22 (3) ◽  
pp. 102-108 ◽  
Author(s):  
H. Bruch
Keyword(s):  
Eating Disorders ◽  
Anorexia Nervosa ◽  
Severe Malnutrition ◽  
Developmental Factors ◽  
Early Experiences ◽  
Number Of Patients ◽  
The Family ◽  
Similarities And Differences ◽  
Early Developmental

This paper emphasizes that neither obesity nor severe malnutrition represents a uniform clinical psychiatric picture. The therapist must always pay attention to and integrate the various factors involved in eating disorders such as the underlying personality problems, resolution of the interactional conflicts within the family and correction of the abnormal nutritional states. The similarities and differences of both obesity and anorexic states are described. Primary or typical anorexia nervosa is differentiated from the atypical kinds. The importance of early developmental factors of how the child differentiates inner and outer stimuli, the appropriate or inappropriate responses to these and the manner in which these early experiences later affect somatic, social and psychological self concepts are discussed. Various parameters and modalities of treatment are described based on the author's long-term experiences with a large number of patients.

Sign in / Sign up

Export Citation Format

Share Document